A Growing Franchise With an Expiration Date
Merck & Co., Inc. is trying to extend its oncology leadership before competition threatens its largest earnings engine. Keytruda and Keytruda Qlex produced $8.4 billion of second-quarter 2026 sales, about half the company’s $16.6 billion worldwide revenue. A therapy that important creates a difficult valuation equation: newer medicines must grow quickly enough to replace eventual lost sales without exhausting the cash those established products generate today.
October developments underline both sides of that problem. Merck & Co., Inc. highlighted pivotal oncology data for the upcoming ESMO meeting and expanded its manufacturing and research investments in Pennsylvania. But Reuters also reported that a Dutch patent court ordered a halt to sales of its subcutaneous Keytruda formulation in eight European markets amid a dispute with Halozyme. Merck contests the ruling. Neither the injunction nor ongoing litigation establishes the ultimate commercial impact, but they complicate a strategy intended to sustain the franchise.
Merck & Co., Inc. ranks third among 11 Best Cancer Stocks to Invest In Now, supported by 101 hedge funds in Q2 2026. What separates its diversified drug pipeline from the two companies ranked higher, and is its large existing oncology revenue a strength or a concentration risk?
360b / Shutterstock.com
Replacement Growth Needs to Be Material
Merck & Co., Inc.’s Q2 revenue rose 5% to $16.6 billion, while Keytruda sales also grew 5%. The more rapidly expanding Winrevair business generated $588 million, up 75%, and Animal Health contributed $1.8 billion, up 8%. Those businesses demonstrate genuine diversification, but Winrevair remains much smaller than the $8.4 billion quarterly Keytruda franchise. The scale gap explains why the company’s latest valuation rally still leaves a Keytruda-replacement question.
Drug development adds an uneven stream of possible replacements. Merck’s voluntary withdrawal of the U.S. application for ifinatamab deruxtecan after regulatory discussions removed a nearer-term approval opportunity, though Phase 3 trials continue.
Other approvals and studies broaden the pipeline. Keytruda-based combinations have expanded into additional breast-cancer settings, while next-generation oncology programs address tumors where existing treatment offers limited benefit. Yet clinical milestones alone cannot fill a multibillion-dollar revenue gap. The latest Keytruda combination approval in aggressive breast cancer illustrates the distinction between broader indications and incremental sales large enough to change group earnings.
The P/E Requires Careful Reading
Merck & Co., Inc.’s August Q2 report included a $2.31-per-share charge tied to the Terns acquisition, producing a GAAP loss of $0.54 per share and a non-GAAP loss of $0.13 per share for the quarter. Full-year 2026 non-GAAP EPS guidance of $2.66–$2.76 includes $2.43 per share of charges related to the transaction. These unusual expenses distort naive comparisons of earnings multiples across years.
The Seeking Alpha data as of October 19 consequently shows 114.66 times trailing GAAP P/E, 106.52 times forward GAAP P/E and 54.94 times forward non-GAAP P/E, versus a 19.13-times sector median on the last measure. Its 2027 estimated earnings multiple falls to 15.76 times as one-time charges roll off. Consensus EPS projections show a 70.41% decline in 2026, followed by a 248.63% rebound in 2027, and 10.12% growth in 2028. This is not evidence of a sudden tripling in underlying drug demand: the earnings recovery is heavily affected by the nonrecurrence of transaction charges.
That distinction matters because a superficially expensive current P/E and cheaper 2027 P/E can both be accurate but misleading in isolation. Investors need to judge a normalized earnings base after one-time charges, expected new-drug launches, and the coming patent challenge.
An Expensive Transition With Limited Margin for Error
Merck & Co., Inc. expects worldwide 2026 sales between $66.3 billion and $67.3 billion. It is also committing $2.9 billion to expand Pennsylvania operations through 2030, including a $550 million robotics- and AI-enabled research and manufacturing facility, according to Reuters. Such capital commitments may strengthen the pipeline but cannot resolve the timing mismatch between patent erosion and launches immediately.
Analyst targets reflect concerns about near-term earnings pressure. Goldman Sachs lowered its price target to $155 from $160 on October 19 while maintaining Buy, citing expectations of softer 2027 earnings as Merck increases spending on drug launches and clinical trials. RBC Capital cut its target to $145 from $150 on October 12, maintaining Sector Perform and reducing its 2026 EPS estimate by $0.21 to $2.52, as elevated investment threatens to limit earnings growth despite resilient revenue.
Insider Monkey tracked 101 hedge funds in Q2, up from 98 in Q1. Short interest declined to 28.27 million shares at September 30 from 30.29 million in August, or 1.15% of float. These snapshots predate the latest legal and clinical updates and are not signals of investor intent.
Merck has multiple credible growth engines. Its valuation will be determined by their combined cash contribution after charges normalize, and whether that contribution arrives before Keytruda’s patent expiration changes the revenue base.
READ NEXT: Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway? and Moderna (MRNA) Soars to Fresh High Ahead of Pipeline Updates This Week
